Site search
2911 results for '' found
Ms Anita Hazard
With over 20 years of nursing experience, in which many of these have been specialising in research and clinical trials at The Alfred, Anita is currently serving as the research lead for the structural heart team. Anita is dedicated and passionate about the role and future of clinical trials in…
/about/bio/ms-anita-hazard
How_to_get_to_Area_U_-_549_St_Kilda_Road_-_Map_v3.pdf
Making_the_Move_to_549_St_Kilda_Road_-_Flyer_v4.pdf
A Phase I/II, open-label, adaptive two-part trial to evaluate the safety, efficacy, optimal dose and pharmacokinetics of BNT326 as monotherapy and in combination with cancer immunotherapies in pa
A Phase I/II, open-label, adaptive two-part trial to evaluate the safety, efficacy, optimal dose and pharmacokinetics of BNT326 as monotherapy and in combination with cancer immunotherapies in pa
/
A Phase 1/2 Study to Assess the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy of HMB-002 in Participants with Von Willebrand Disease (NCT06754852)
A Phase 1/2 Study to Assess the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy of HMB-002 in Participants with Von Willebrand Disease (NCT06754852)
/
A Phase 3 Study to Assess the Efficacy and Safety of Midbrain Dopaminergic Neuronal Cell Therapy [Bemdaneprocel] for Patients with Parkinsons Disease [PD] (NCT06944522)
A Phase 3 Study to Assess the Efficacy and Safety of Midbrain Dopaminergic Neuronal Cell Therapy [Bemdaneprocel] for Patients with Parkinsons Disease [PD] (NCT06944522)
/
Relapsed or Refractory Multiple Myeloma: Dose Escalation and Expansion of Etentamig in Combination with a CELMoD agent (NCT06896916)
Relapsed or Refractory Multiple Myeloma: Dose Escalation and Expansion of Etentamig in Combination with a CELMoD agent (NCT06896916)
/
A Phase IIb, open label, sequential cohort study comparing KappaMab alone to KappaMab in combination with lenalidomide and low dose dexamethasone [MRd] in Relapsed Refractory Multiple Myeloma (AC
A Phase IIb, open label, sequential cohort study comparing KappaMab alone to KappaMab in combination with lenalidomide and low dose dexamethasone [MRd] in Relapsed Refractory Multiple Myeloma (AC
/
A Phase 2a, Two-Part, Open-Label and Randomized Study to Evaluate the Safety and Efficacy of OD-07656 and of Subsequent Vedolizumab Therapy in Patients with Moderately to Severely Active Ulcerati
A Phase 2a, Two-Part, Open-Label and Randomized Study to Evaluate the Safety and Efficacy of OD-07656 and of Subsequent Vedolizumab Therapy in Patients with Moderately to Severely Active Ulcerati
/